期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

长期低剂量皮下注射鱼藤酮制作大鼠帕金森病模型 被引量：27

Chronic subcutaneous injection of rotenone produces rodent Parkinsonian models
下载PDF
导出
摘要 目的研究长期低剂量皮下注射鱼藤酮制作Lew is大鼠帕金森病模型。方法Lew is大鼠随机分为正常对照组和模型组,以1.0 mg.kg-1.d-1的剂量皮下注射鱼藤酮,早晚2次注射,连续给药30 d,每周停药1 d。给药结束后,心脏灌注多聚甲醛固定,断头取脑,免疫组化和尼氏染色检测黑质(SN)多巴胺神经元损伤情况,并在共聚焦显微镜下观察α-synuc le in的聚集。结果模型组大鼠3只出现震颤。SN处酪氨酸羟化酶(TH)阳性细胞数也出现不同程度的减少,尼氏染色显示SN神经元减少,并伴有胶质细胞增生,黑质多巴胺能细胞胞浆内有-αsynuc le in阳性聚集体,模型成功率约为58%。结论长期皮下注射鱼藤酮(1.0 mg.kg-1.d-1)可复制大鼠帕金森病病理模型。 Aim To establish a rat model of Parkinsons disease by chronic subcutaneous injection of low-dose rotenone. Methotis Lewis rats were randomly divided into two groups： vehicletreated group and rotenone-treated group. Rotenone （ 1.0 mg · kg^-1 · d ^-1 ） was subcutaneously injected at 08 ： 00 and 20 ： 00 for 30 days with drug holidays every 7 days. Following 30 days of rotenone administration, neuronal loss in the substantia nigra （ SN ） was determined with tyrosine bydroxylase （ TH ） immunohistochemistry and Nissl staining. Aggregation of α-synuclein in SN neurons was observed with a laser cofocal microscopy. Resuit Three rotenone-treated rats showed resting tremor. The number of TH-positive neurons in SN significantly reduced （ P 〈 0. 05）. Gliosis was observed in SN of rotenone-treated rats and α-synuclein-positive inculsion was found in the cytoplasm of SN neurons. The percentage of rotenone-treated rats with significant SN lesion was 58%. Conclusion Subcutaneous injection of low dose of rotenone （ 1.0 mg·kg^-1·d^-1 produces Parkinsoniasm in Lewis rats with low mortality and high successful rate.
作者 赵喜林 顾振纶 秦正红
机构地区 苏州大学医学院药理教研室.苏州中药研究所
出处 《中国药理学通报》 CAS CSCD 北大核心 2005年第10期1274-1277,共4页 Chinese Pharmacological Bulletin
基金 香港保健协会科研基金资助项目(No20030816)
关键词 鱼藤酮 帕金森病 黑质 酪氨酸羟化酶 Α-SYNUCLEIN rotenone parkinsons disease substantia nigra tyrosine hydroxylase α-synuclein
分类号 R-332 [医药卫生] R329.24 [医药卫生—人体解剖和组织胚胎学]
  • 相关文献

参考文献15

  • 1Betarbet R, Sherer TB, Mackenzie et nl. Chronic systemic pesticide exposure reproduces features of Parkinson's disease[J]. Nat Neurosci, 2000,3 ( 12 ) : 1301 - 6.
  • 2李云鹏,董兆君,王仕丽,蔡颖,李奇慧,乐卫东.重复注射鱼藤酮对中枢多巴胺神经元的毒性作用[J].第三军医大学学报,2003,25(13):1123-1126. 被引量：19
  • 3Ferrante RJ, Schulz JB, Kowall NW et al. Systemic administration of rotenone produces selective damage in striatum and globus pallidus, but not in the substantia nigra[J]. Brain Res, 1997,753(1):157-62.
  • 4Fang N, Rowlands JC, Casida JE et al. Anomalors structure-activity relationships of 13-homo-13-oxarotennids and 13-homo-13-oxadehy drorotenoids[J]. Chem Res Toxicol, 1997,10 ( 8 ) :853 - 8.
  • 5Hollingworth RM, Ahammadsahib KI, Gadelak G et al. New inhibitors of complex I of the mitochondrial electron transport chain with activity as pesticide[J]. Biochem Soc Trans, 1994,22 ( 1 ) :230 - 3.
  • 6RFriedrich T, Ohnishi T, Forche E et al. Two binding site for naturally occurring inhibitor in mitochondrial and bacterial NADH:ubiquinone oxidoreductase (complex Ⅰ )[J]. Biochem Soc Trans,1994 ,22(1):226 -30.
  • 7Li N, Ragheb K, Lawler Get al. Mitochondrial complex Ⅰ inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production[J]. Biological Chemistry, 2003,278(10) :8516 -25.
  • 8He Y, Imam SZ, Dong Z et al. Role of nitric oxide in rotenone-induced nigro-striatal injury[J]. Neurochemistry, 2003,86 ( 6 ) :1338 -45.
  • 9Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons[J]. Neurosci, 2003 ;23 ( 15 ) :6181 - 7.
  • 10Ling Z,Chang QA, Tong CW et al. Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally[J]. Exp Neurol, 2004,190(2) :373 -83.

二级参考文献30

  • 1Dawson TM, Dawson VL. Neuroprotective and neurorestorative strategies for Parkinson's disease[J]. Nat Neurosci, 2002, Suppl:1058-61.
  • 2Patterson SD,Spahr CS,Daugas E et al. Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition[J]. Cell Death Differ, 2000, 7: 137-44.
  • 3Schapira AHV. Mitochondrial involvement in Parkinsons disease, Huntington's disease, hereditary spastic paraplegia and Friedrich's ataxia[J]. Biochim Biophys Acta, 1999, 1410:159-70.
  • 4Swerdlow RH, Parks JK, Miller SW et al.Origin and functional consequences of the complex I defect in Parkinsons disease[J]. Ann Neurol, 1996,40(4):663-71.
  • 5Walt JM, Nicodemus KK, Martin ER et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease[J]. Am J Hum Genet, 2003,72 (4):804-11.
  • 6McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinsons disease[J]. Ann Neurol, 2003, 53 (Suppl 3):73-84.
  • 7Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila[J]. Nat Med, 2002,8 (11):1185-6.
  • 8Auluck PK, Chan HYE, Trojanowski JQ et al.Chaperone suppression of alpha-synuclein toxicity in a drosophila model for Parkinsons disease[J]. Science,2002,295(5556): 865-68.
  • 9Quigley PM, Korotkov K, Baneyx F et al. The 1.6-crystal structure of the class of chaperones represented by Escherichia coli Hsp31 reveals a putative catalytic triad[J]. Proc Natl Acad Sci USA, 2003, 100 (6): 3137-42.
  • 10Giasson BI, Duda JE, Murray IV et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions[J]. Science, 2000, 290:985-9.

共引文献29

同被引文献214

引证文献27

二级引证文献165

中国药理学通报
2005年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部